Special Issue

The Role of Tissue Factor and Downstream Coagulation Proteases in Solid Cancers and Hematological Malignancies

Message from the Guest Editor

In 1865, the French physician Armand Trousseau described the association between gastrointestinal cancer and superficial migratory thrombophlebitis. Trousseau himself succumbed to gastric or pancreatic cancer after he noticed an inflamed and thrombosed vein, nowadays referred to as the "Trousseau's sign of malignancy."

TF is a transmembrane glycoprotein that functions as the cellular receptor and cofactor for the coagulation serine protease, factor VIIa (FVIIa). TF is constitutively expressed by many cancer cells and may also be induced in non-transformed cells of the tumor microenvironment under inflammatory or hypoxic conditions.

Moreover, circulating TF has emerged as a potential diagnostic, prognostic and predictive biomarker in solid cancers and hematological malignancies.

This Special Issue of Cancers focuses on the intriguing roles of TF and downstream coagulation proteases in tumor biology and paraneoplastic clotting abnormalities, thus setting the base for future experimental and clinical research investigating the detrimental bidirectional relationships between cancer, inflammation and thrombosis.

Guest Editor

Prof. Dr. Florian Langer

Department of Hematology and Oncology, University Cancer Center Hamburg (UCCH), University Medical Center Eppendorf, Martinistr. 52, 20246 Hamburg, Germany

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/62535

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

